From the Journals

Elbasvir, grazoprevir beat HCV despite compensated cirrhosis


Key clinical point: Twelve weeks of combination therapy with elbasvir and grazoprevir was relatively well tolerated and achieved sustained viral response for most patients with chronic genotype 1, 4, or 6 hepatitis C virus infections and compensated cirrhosis.

Major finding: Rates of sustained virologic response were 98% for treatment-naive patients and 89% for treatment-experienced patients.

Data source: An integrated analysis of 402 patients with treatment-naive or treatment-experienced HCV GT1, 4, or 6 infection and compensated, Child-Pugh A cirrhosis.

Merck, which funded the study, makes elbasvir and grazoprevir. The investigators acknowledged medical writing and editorial assistance from ApotheCom, which Merck funded. Dr. Jacobson disclosed consulting relationships and grant funding from Merck, AbbVie, Bristol-Myers Squibb, Gilead, Intercept, Janssen, and Trek.




Twelve weeks of combination therapy with elbasvir and grazoprevir (EBR/GZR) achieved sustained virologic response in 98% of treatment-naive patients with compensated cirrhosis and chronic hepatitis C (HCV) genotype 1, 4, or 6 infections, and in 89% of treatment-experienced patients, according to a pooled analysis of six industry-sponsored trials.

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge

Next Article: